



July 1, 2024

**Notice to Covered Entities Regarding 340B Contract Pharmacy Policy
Mylan Specialty L.P. and Viatriis Specialty LLC**

Dear Covered Entity:

We are writing to notify you that, beginning August 1, 2024, Mylan Specialty L.P. and Viatriis Specialty LLC (collectively "Viatriis") is revising its policy regarding distribution of certain Viatriis products, listed in Attachment A to this letter ("applicable products") via contract pharmacy arrangements. Viatriis supports the 340B program's mission of improving vulnerable patients' access to needed medications. Viatriis is undertaking this policy change in response to persistent and increasing concerns about the integrity of the 340B program, particularly in connection with diversion and duplicate discounts amidst the proliferation of contract pharmacy arrangements. Viatriis's policy change helps to mitigate these concerns, thereby enhancing the integrity and sustainability of the program.

Effective August 1, 2024, Viatriis will ship applicable products exclusively to locations registered in the 340B OPAIS database as a covered entity, a child site location, or as a contract pharmacy location subject to the parameters described below.

Viatriis will permit covered entities without an in-house pharmacy to designate a single contract pharmacy location to receive bill to/ship to orders of applicable products at the 340B price. Covered entities must designate their single contract pharmacy location via the 340B ESP™ platform at <https://www.340besp.com/designations>. Designations must be made by July 19, 2024, in order for the designation to take effect on the effective date of this policy change. Viatriis will permit covered entities to change their designation once every twelve months, or upon the expiration of the contract between the covered entity and single-designated contract pharmacy.

This policy change will apply to hospital covered entities and Community Health Center (CHC) federal grantee covered entities. Non-CHC federal grantee covered entities will be exempt from this policy change.

In addition, this policy change will not apply to contract pharmacy arrangements in Arkansas, Louisiana, West Virginia, Mississippi, Kansas, Maryland and Minnesota.

This policy and the list of applicable products may be updated from time to time and will be posted at <https://www.340besp.com/resources>.

We look forward to working with you in support of a smooth transition to our new policy. Please contact us at support@340Besp.com if you have any questions or require assistance.



Attachment A
List of Applicable Products
Subject to Viatriis Contract Pharmacy Policy Change
August 1, 2024

Celebrex® (celecoxib) Capsules
Effexor XR® (venlafaxine HCl) Extended-Release Capsules
EMSAM® (selegiline transdermal system)
EPINEPHRINE Injection, USP Auto-Injectors
EPIPEN® (epinephrine injection, USP) Auto-Injector 0.3 mg
EPIPEN Jr® (epinephrine injection, USP) Auto-Injector 0.15 mg
FELBATOL® (felbamate) Oral Suspension
FELBATOL® (felbamate) Tablets
Lipitor® (atorvastatin calcium) Tablets
Lyrica® (pregabalin) Capsules
Neurontin® (gabapentin) Capsules
Neurontin® (gabapentin) Tablets
Norvasc® (amlodipine besylate) Tablets
PERFOROMIST® (formoterol fumarate) Inhalation Solution
Relpax® (eletriptan HBr) Tablets
Revatio® (sildenafil) for Oral Suspension
Revatio® (sildenafil) Injection
Revatio® (sildenafil) Tablets
Viagra® (sildenafil citrate) Tablets
Xalatan® (latanoprost) Ophthalmic Solution
Xanax® (alprazolam tablets, USP)
YUPELRI® (revefenacin) inhalation solution
Zoloft® (sertraline hydrochloride) Tablets

The applicable products are marketed with NDCs under Viatriis labeler codes 00037, 49502 and 58151, as well as some legacy NDCs under non-Viatriis labeler codes 00008, 00009, 00013, 00025, 00049, 00069, 00071.